The short answer on candidacy

ChondroFiller is generally suited to adults with a focal, contained area of cartilage damage in the knee — where the wear is localised rather than spread across the whole joint surface. The two factors that matter most at the outset are how deep the damage goes (ICRS Grade III or IV on the cartilage grading scale) and how large the affected area is (up to 6 cm²).

Beyond those two gatekeepers, the picture is more flexible than many patients expect. Because ChondroFiller is an acellular scaffold — meaning it carries no cells of its own and instead recruits the patient's own progenitor cells from the surrounding joint tissue — its eligibility is not tied to cell-harvest viability. There is no fixed upper age limit for the outpatient injectable pathway, and no stated BMI threshold equivalent to those applied to certain surgical options. Patients who have been advised they are too old or too heavy for a particular operation may still be appropriate candidates.

The treatment is delivered as an ultrasound-guided injection in an outpatient clinic setting — not a theatre procedure. Each of the qualifying criteria is covered in detail in the sections below.

Cartilage grade and the ICRS scale

The ICRS scale runs from 1 to 4, and the difference between grades is not merely academic — it determines whether the scaffold has enough structural depth to fulfil its purpose.

Grade 1 is surface softening: the cartilage feels spongy but remains mostly intact in cross-section. Grade 2 describes cracks or fissures reaching less than halfway through the cartilage thickness — early damage without substantial volume loss. Neither qualifies for ChondroFiller; the collagen matrix needs a defect with real depth if the patient's own progenitor cells are to migrate into it and begin the repair process.

Grade 3 is the entry threshold: cartilage loss extends to more than 50% of the original thickness, sometimes reaching the calcified layer above the subchondral bone. Grade 4 — full-thickness loss with exposed subchondral bone — is also within scope. Picture the progression as surface cracking (Grades 1–2), a deepening pothole (Grade 3), and an exposed pit reaching the underlying bone structure (Grade 4). Both of the deeper categories produce the kind of void the scaffold is designed to fill.

Diffuse wear rather than a single focal defect

The common assumption is that severe osteoarthritis automatically disqualifies a patient — but the picture is more nuanced for single-compartment disease. Patients with Kellgren-Lawrence Grade III or IV osteoarthritis concentrated in one compartment of the knee may still be eligible. The synovial lining and remaining subchondral bone in a joint at this stage retain viable progenitor cells capable of migrating into the scaffold; an ex vivo osteochondral study recorded a 2.4-fold increase in DNA content within ChondroFiller® by day 14, confirming this cell-recruitment mechanism. What disqualifies is pan-articular, end-stage osteoarthritis spread diffusely across multiple compartments, where insufficient healthy tissue remains to supply that cellular environment.

Once the grade is confirmed, the treating clinician maps defect depth and containment using MRI cartilage-sensitive sequences including T2 mapping — at Lincolnshire Knee, the onMRI™ platform's cartilage segmentation tools support this pre-injection assessment.

Defect size: what the 6 cm² ceiling means

Six square centimetres is roughly the surface area of a 50p coin — a useful reference point when thinking about what ChondroFiller's size ceiling means in practice. Microfracture, the most common surgical first-line approach to cartilage repair, is generally considered appropriate only for lesions below approximately 2–4 cm². The SUMMIT trial evidence indicates that defects of 3 cm² or more tend to achieve better outcomes with MACI (membrane autologous chondrocyte implantation), a more involved cell-based surgical procedure requiring theatre admission. ChondroFiller's upper limit of 6 cm² sits above both thresholds, covering a range of lesion sizes that conventional alternatives either handle poorly or require general anaesthesia to address.

Why containment matters as much as size

The scaffold is placed in liquid form under ultrasound guidance and gels in situ within the defect. For that to work, the damage needs to be contained — surrounded on all sides by structurally intact cartilage that acts as a retaining wall. Without healthy borders, the collagen matrix cannot maintain its position, and the repair environment it creates is compromised. Defect geometry therefore forms part of the eligibility assessment, not just measured area.

At the smaller end of the spectrum, lesions below roughly 2 cm² may respond adequately to less invasive interventions. Defects approaching or exceeding 6 cm² warrant surgical evaluation instead. Crucially, sizing and containment are confirmed by MRI before the injection appointment — a prior arthroscopy is not a prerequisite for assessment.

Age and BMI: what the evidence actually says

Two characteristics tend to generate the most patient concern at the assessment stage — age and body weight — and on both fronts the evidence is more permissive than patients typically expect.

Age

Published clinical series have enrolled relatively young cohorts: the 17-patient knee study reported a mean age of 31 years. That skew reflects the demographics of focal traumatic cartilage injury, not a ceiling on eligibility. Clinical practice documentation consistently records use in patients in their 60s, 70s, and beyond as a joint-preservation step before any consideration of knee replacement — and no fixed upper age limit appears in the eligibility criteria.

The reason age-related concern does not transfer here is straightforward: because the scaffold is acellular (as described in the opening section), the worries about donor-cell viability that apply to procedures such as autologous chondrocyte implantation simply do not arise. Cell-harvest suitability is not a variable.

BMI

No specific upper BMI threshold for the injectable ChondroFiller pathway has been formally reported in peer-reviewed literature — this is an acknowledged gap in the published evidence base. For context, donor-site procedures such as OATS carry a relative contraindication above BMI 40, because tissue harvest and surgical access are constrained by body habitus. ChondroFiller requires neither; the injectable pathway involves an outpatient, ultrasound-guided placement with no tissue removed.

Obesity is, nonetheless, a recognised modifier of knee cartilage load. Higher body mass increases mechanical stress on articular surfaces over time, and this is worth discussing as part of longer-term joint protection planning — particularly around weight-bearing rehabilitation and load management. That discussion is part of a shared decision-making conversation with the treating clinician, not a basis for ruling out the injection itself.

When ChondroFiller is not appropriate

Collagen allergy, active infection, and metabolic joint disease sit at the top of the exclusion list — conditions where the treatment cannot safely proceed regardless of the cartilage findings. Specifically: a known allergy to murine, bovine, or porcine collagen (the scaffold is murine-derived), an active joint infection, and metabolic arthropathy such as gout. These are absolute contraindications.

Structural factors form a second category. Uncorrected ligament instability, significant knee malalignment of more than 5°, and major meniscal absence all undermine the joint mechanics the scaffold relies on. In some cases these can be addressed first, potentially reopening the pathway — a clinician can advise whether that applies to a specific presentation.

The third category is advanced pan-articular disease: deterioration spread across multiple compartments of the knee rather than concentrated in one area. A focal injectable scaffold is not designed for whole-joint degeneration. As noted in the section on cartilage grade, single-compartment disease at Kellgren-Lawrence Grade III or IV is a different finding and may still fall within scope. Where multi-compartmental end-stage change is confirmed, the relevant conversation moves towards osteotomy or knee replacement planning.

Not qualifying for ChondroFiller does not leave a patient without options. A structured clinical assessment identifies which pathway — a different injection, a surgical approach, or a managed conservative plan — best fits the specific pattern of damage and the patient's priorities.

How assessment works at Lincolnshire Knee

Determining whether ChondroFiller is the right option begins with a structured consultation — clinical history, physical examination of the knee, and review of imaging. Where MRI has not yet been performed, cartilage-sensitive sequences are arranged to confirm defect grade, size, and whether the surrounding borders are intact. These findings, taken together, form the basis of an eligibility discussion.

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without a GP referral. There is no NHS-style waiting list. Consultations and diagnostics are available at two sites: Sleaford (NG34), which houses the Regeneration Hub and Open MRI facility, and Grantham (NG31) for consultation and diagnostic appointments.

For patients where loading pattern and gait mechanics are relevant to joint stress or rehabilitation planning, objective biomechanical assessment using MAI Motion® can contribute useful context alongside the imaging picture.

ChondroFiller itself is delivered as an outpatient, ultrasound-guided injection. There is no hospital admission and no general anaesthetic involved — patients are typically seen and treated within a single appointment slot.

To book an assessment, visit lincolnshireknee.co.uk.